Literature DB >> 27640873

Extended half-life factor VIII for immune tolerance induction in haemophilia.

L M Malec1,2, J Journeycake3,4, M V Ragni1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27640873     DOI： 10.1111/hae.13064

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  14 in total

1.  Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.

Authors:  Katalin Kis-Toth; Gaurav Manohar Rajani; Allison Simpson; Kate L Henry; Jennifer Dumont; Robert T Peters; Joe Salas; Christine Loh
Journal:  Blood Adv       Date:  2018-11-13

Review 2.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

Review 3.  Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India.

Authors:  Tulika Seth
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-04       Impact factor: 0.900

4.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10

Review 5.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

Review 6.  Novel approaches to hemophilia therapy: successes and challenges.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

Review 7.  From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.

Authors:  David W Scott
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 8.  Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Authors:  Kenneth Lieuw
Journal:  J Blood Med       Date:  2017-06-15

Review 9.  Emerging therapies for hemophilia: controversies and unanswered questions.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  F1000Res       Date:  2018-04-24

10.  Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor.

Authors:  Maria T Georgescu; Paul C Moorehead; Tongyao Liu; Jennifer Dumont; David W Scott; Christine Hough; David Lillicrap
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.